Search Results - "Schultz, Neil"

Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review by Schultz, Neil M., Bhardwaj, Shweta, Barclay, Claudia, Gaspar, Luis, Schwartz, Jason

“…Age-related macular degeneration (AMD) is a leading cause of blindness, particularly in higher-income countries. Although dry AMD accounts for 85% to 90% of…”
Get full text

Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden by Nappi, Rossella E., Kroll, Robin, Siddiqui, Emad, Stoykova, Boyka, Rea, Carol, Gemmen, Eric, Schultz, Neil M.

“…To determine prevalence and health-related quality of life (HRQOL) of moderate-to-severe vasomotor symptoms (VMS) in postmenopausal women in Europe, the US,…”
Get full text

Prevalence and quality-of-life burden of vasomotor symptoms associated with menopause: A European cross-sectional survey by Nappi, Rossella E., Siddiqui, Emad, Todorova, Lora, Rea, Carol, Gemmen, Eric, Schultz, Neil M.

“…•A high proportion of postmenopausal women reported experiencing moderate-to-severe vasomotor symptoms in this European survey.•The severity of vasomotor…”
Get full text

Psychometric evaluation of the PROMIS SD-SF-8b instrument in individuals experiencing vasomotor symptoms due to menopause by Schultz, Neil M, Morga, Antonia, Siddiqui, Emad, Rhoten, Stephanie E

“…Abstract Background Women with vasomotor symptoms (VMS) due to menopause frequently experience poor sleep quality. The Patient-Reported Outcomes Measurement…”
Get full text

Psychometric Evaluation of the MENQOL Instrument in Women Experiencing Vasomotor Symptoms Associated with Menopause by Schultz, Neil M., Morga, Antonia, Siddiqui, Emad, Rhoten, Stephanie E.

“…Introduction Vasomotor symptoms (VMS) associated with menopause can negatively affect health-related quality of life (HRQoL). The Menopause-Specific Quality of…”
Get full text

Correction to: Psychometric Evaluation of the MENQOL Instrument in Women Experiencing Vasomotor Symptoms Associated with Menopause by Schultz, Neil M., Morga, Antonia, Siddiqui, Emad, Rhoten, Stephanie E.

Get full text

Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis by Tanaka, Yoshiya, Takeuchi, Tsutomu, Izutsu, Hiroyuki, Kaneko, Yuichiro, Kato, Daisuke, Fukuda, Musashi, Rokuda, Mitsuhiro, Schultz, Neil M.

“…Abstract Background Peficitinib (ASP015K), a novel oral Janus kinase inhibitor, has demonstrated efficacy and safety in the treatment of patients with…”
Get full text

Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States by Stute, Petra, Cano, Antonio, Thurston, Rebecca C., Small, Mark, Lee, Lauren, Scott, Megan, Siddiqui, Emad, Schultz, Neil M.

“…•Vasomotor symptoms associated with menopause adversely affected sleep, mood, and quality of life.•In this study, over 25 % of women with vasomotor symptoms…”
Get full text

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate by Tagawa, Scott T., Ramaswamy, Krishnan, Huang, Ahong, Mardekian, Jack, Schultz, Neil M., Wang, Li, Sandin, Rickard, Lechpammer, Stanislav, George, Daniel J.

“…Objective Evaluation of the comparative effectiveness of enzalutamide and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer by George, Daniel J., Ramaswamy, Krishnan, Huang, Ahong, Russell, David, Mardekian, Jack, Schultz, Neil M., Janjan, Nora, Freedland, Stephen J.

“…Background Black men are more likely to be diagnosed with aggressive prostate cancer (PC) and die from PC than white men. However, black men with metastatic…”
Get full text

Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer by Schultz, Neil M, O'Day, Ken, Sugarman, Rebecca, Ramaswamy, Krishnan

“…Prostate cancer is the most common cancer and second-leading cause of cancer death among men in the United States. Prostate cancer poses a large economic…”
Get full text

Epidemiology and treatment patterns of UK women diagnosed with vasomotor symptoms: Findings from the Clinical Practice Research Datalink GOLD database by Kiran, Amit, Schultz, Neil M., Siddiqui, Emad, Todorova, Lora, Van der Poel, Bas, Stoelzel, Matthias, Robinson, Lynne

“…•This study found the incidence of vasomotor symptoms to be stable over the period 2009–2018 for women aged 40–65 years.•A third and a half of women diagnosed…”
Get full text

Corrigendum to “Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States” [Maturitas 164 (October 2022) 38–45] by Stute, Petra, Cano, Antonio, Thurston, Rebecca C., Small, Mark, Lee, Lauren, Scott, Megan, Siddiqui, Emad, Schultz, Neil M.

Get full text

Plain language summary: Does the amount of time it takes for prostate-specific antigen to double affect how long men with nonmetastatic castration-resistant prostate cancer live and their healthcare costs? by Freedland, Stephen J, Ramaswamy, Krishnan, Huang, Ahong, Sandin, Rickard, Schultz, Neil M, Janjan, Nora, George, Daniel J

“…WHAT IS THIS SUMMARY ABOUT?This is a plain language summary of a research article originally published in Clinical Genitourinary Cancer. The original article…”
Get full text

Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer by Freedland, Stephen J., Ramaswamy, Krishnan, Huang, Ahong, Sandin, Rickard, Mardekian, Jack, Schultz, Neil M., Janjan, Nora, George, Daniel J.

“…•Most patients with nmCRPC have PSADT >12 months and a long natural history.•However, for those with shorter PSADT, the risk of metastasis and death, as well…”
Get full text

Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis by Schultz, Neil M., Penson, David F., Wilson, Samuel, Song, Yan, Yang, Hongbo, Ramaswamy, Krishnan, Lowentritt, Benjamin

“…Introduction Corticosteroids are a mainstay treatment for castration-resistant prostate cancer (CRPC). Although corticosteroids have been associated with…”
Get full text

Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis by Schultz, Neil M., Flanders, Scott C., Wilson, Samuel, Brown, Bruce A., Song, Yan, Yang, Hongbo, Lechpammer, Stanislav, Kassabian, Vahan

“…Introduction Enzalutamide and abiraterone acetate (plus prednisone) are new hormonal treatments for metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide? by George, Daniel J, Ramaswamy, Krishnan, Huang, Ahong, Russell, David, Schultz, Neil M, Janjan, Nora, Freedland, Stephen J

“…This is a summary of a research article originally published in . There were few Black men in the clinical trials that led to the approval of the medications…”
Get full text

Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone by Ramaswamy, Krishnan, Lechpammer, Stanislav, Mardekian, Jack, Huang, Ahong, Schultz, Neil M., Sandin, Rickard, Wang, Li, Baser, Onur, George, Daniel J.

“…Introduction Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for considerable healthcare expenditures. We evaluated…”
Get full text

The Patient Experience: Symptoms and Impact of Dry Age-Related Macular Degeneration by Schultz, Neil M., Braunack-Mayer, Lydia, Schwartz, Jason, Gaspar, Luis

“…Introduction No published literature systematically explores the dry age-related macular degeneration (AMD) patient experience. To inform the development of…”
Get full text